NMDA antagonist prodrugs
AssigneeAstraZeneca AB
InventorsGunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
Life of this patent
Estimating the term…
Abstract
Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
Claims10
A method of treating depression, comprising administering to a patient in need thereof a pharmaceutical composition comprising from 0.10 to 50% by weight of compound that is (S)-1((S)-2-amino-3-methylbutanoyl)-N-((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A method of treating pain, comprising administering to a patient in need thereof a pharmaceutical composition comprising from 0.10 to 50% by weight of compound that is (S)-1((S)-2-amino-3-methylbutanoyl)-N-((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A method of treating a disease selected from the group consisting of Rett Syndrome, suicidal ideation, bipolar disorder, obsessive compulsive disorder, sarin gas poisoning, and status epilepticus, comprising administering to a patient in need thereof a pharmaceutical composition comprising from 0.10 to 50% by weight of compound that is (S)-1((S)-2-amino-3-methylbutanoyl)-N-((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.